Vermillion Files 510(k) with FDA for Ovarian Tumor Triage Test | GenomeWeb
NEW YORK (GenomeWeb News) – Vermillion said today that it has filed for clearance from the US Food and Drug Administration for its OVA1 Ovarian Tumor Triage Test.
The OVA1 test was developed as part of an alliance between Vermillion and Quest Diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.